TMCNet:  iCAD Launches New VersaVue MR Software at RSNA 2012

[November 25, 2012]

iCAD Launches New VersaVue MR Software at RSNA 2012

CHICAGO --(Business Wire)--

iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, announced today it will launch VersaVue Enterprise 3.2.1, the latest release of the company's MR software solution that provides improvements in workflow efficiency and flexibility, at the annual conference of the Radiological Society of North America (RSNA) taking place in Chicago, November 25-30.

"iCAD (News - Alert) is committed to developing the most comprehensive, sophisticated image analysis solutions to help clinicians increase efficiency and diagnostic confidence," said Ken Ferry, President and CEO of iCAD. "The new VersaVue Enterprise solution will improve workflow and flexibility to aid clinical decision making and treatment for patients, with an ultimate goal of delivering improved patient care."

VersaVue provides robust Dynamic Contrast Enhanced (DCE) MR image analysis and flexible review and reporting tools that facilitate standardization of kinetic analysis and interpretation and reporting of morphology. Using advanced thin client architecture, VersaVue delivers real-time data access and eliminates the need to purchase redundant hardware. The software features on-demand viewing of studies anytime, anywhere to speed workflow as well as shared knowledge of study status from a single, shared database. Unique features of VersaVue Enterprise 3.2.1 include:

  • Fusion of ADC (News - Alert) color overlays on any sequence
  • On the fly 3 time point calculation (Quick TP)
  • Fully automatic prostate segmentation of the capsule that will allow prostate volume reporting

VersaVue Enterprise is part of iCAD's complete MRI product suite which includes SpectraLook®, VividLook® and OmniLook®. These products offer comprehensive quantitative image analysis for cancer detection, staging, localization, treatment planning and serial monitoring.

iCAD will also be highlightin two prostate biopsy solutions at RSNA:


This solution will be a second generation system that will take advantage of the MR scanners gradient fields along with an innovative biopsy needle positioning device that is designed to provide radiologists with easier patient set-up, reduce the number of scans to identify and calculate target coordinates and reduce the total patient time in the magnet. The MRI guided solution is a works in progress project.

The current TRUS procedure has limitations in target hit rate and accuracy. This next generation solution will improve target hit rate and accuracy, color coding significant tracks by Gleason scores and storing those tracks to compare for repeat biopsies particularly important for patients under active surveillance. The system uses a unique organ based tracking technology using 3D end-fire ultrasound probe and elastic Fusion technology to fuse MR with US images. MR TRUS Fusion is a solution that has product compatibility with the VersaVue Enterprise MR solution. With VersaVue Enterprise 3.2.1 release there will be expanded features that will be compatible with the MR TRUS Fusion solution.

Additionally, iCAD's workstation was used to process the MR images used in a neuroradiology study that examined brain meningiomas. A scientific paper presenting the study's findings titled, "Intracranial Tumor Extravascular Extracellular Space: Examining the Correlation Between ADC and DCE MRI Metrics in Human Meningioma," will be presented at RSNA on Tuesday, November 27 at 3:30 p.m. in room N226.

iCAD will also showcase its next generation computer-aided detection (CAD) system for digital mammography, the PowerLook Advanced Mammography Platform (AMP). The modular design of PowerLook AMP provides radiologists with the ability to customize their CAD solution to meet the needs of their individual work environment today and in the future. The technology expands on iCAD's SecondLook Digital solution and is the CAD platform upon which all future breast imaging CAD offerings from iCAD will be built. PowerLook AMP's CAD metrics offer industry-leading tissue and lesion characteristics to support the breast imager's workflow. In addition, PowerLook AMP is the first product of its kind to integrate Matakina's Volpara® Volumetric Breast Density assessment software that aids radiologists by standardizing their approach to breast density assessment.

About iCAD, Inc.

iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD's Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. For more information, call (877) iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.


[ Back To Cloud Computing 's Homepage ]